Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.47 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | SNCA | P37840 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16628751 | 0.88 | CACNA1B (0.56) | ADORA3KMT2ACACNA1BAPBA1ADORA2A | |
| SCHEMBL29246641 | 0.81 | GAA (0.60) | KMT2AGAAMAPTSNCANPC1 | |
| SCHEMBL3086939 | 0.80 | NPC1 (0.53) | ADORA3KMT2AAPPNPC1RAB9A | |
| SCHEMBL16628820 | 0.78 | ADORA3 (0.68) | ADORA3KMT2AAPPCACNA1BAPBA1 | |
| SCHEMBL16628808 | 0.78 | ADORA2A (0.55) | ADORA3ADORA2AMAPTADORA1ADORA2B | |
| SCHEMBL16628794 | 0.78 | ADORA3 (0.58) | ADORA3KMT2AAPPADORA2AMAPT | |
| SCHEMBL3081056 | 0.77 | ADORA2A (0.70) | ADORA3APPADORA2AMAPTADORA1 | |
| SCHEMBL16628837 | 0.76 | ADORA3 (0.58) | ADORA3KMT2AADORA2AGAAMAPT | |
| SCHEMBL3089577 | 0.76 | ADORA2A (0.65) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL3087918 | 0.75 | ADORA3 (0.62) | ADORA3APPADORA2AGAAADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2164833-B1 | Quinazolinamide derivatives useful for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2015-04-15 | — | — | EP | claimed |
| US-8501754-B2 | Quinazolinamide derivatives | MERCK PATENT GMBH (DE) | 2013-08-06 | — | — | US | claimed |
| US-20100234324-A1 | Quinazolinamide derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234324-A1 | Quinazolinamide derivatives | HSP90AB1, HSP90AA1, HSP90AB2P | ADORA3 3301/4885ABCB1 82/4885KMT2A 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.